Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs. 4. Patients will be evaluated every 6 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stomach Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Neoplasms Neoplasms by Site Stomach Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Samsung Medical Center

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age>-20
metastatic gastric cancer
life expectancy >-3 months
ascites and pleural effusion that can be drained
ECOG 0-2
Proper organ function
Patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial

Exclusion criteria

HBeAg, HCV, HIV (+)
Active infection
Uncontrolled systemic disease

Treatment and study plan

Sunitinib

Drug

sunitinib 37.5mg daily

Gefitinib

Drug

Gefitinib 250mg daily

Imatinib

Drug

Imatinib 400mg daily

Primary outcomes

response rate

Time frame: 2 years

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Important dates

Study start: 2017
Primary completion: 2021
Study completion: 2021
First posted: May 30, 2017
Registry last updated: Jun 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed